Tacrolimus for the Management of Delayed Onset and Treatment-Refractory Immune-Related Hepatitis

Immune checkpoint inhibitors, such as pembrolizumab, are effective in the management of metastatic malignancies, such as melanoma, and are associated with a spectrum of immune-related organ toxicities, including immune-related hepatitis (ir-hepatitis). The clinical presentation of ir-hepatitis varie...

Descripción completa

Detalles Bibliográficos
Autores principales: Ea, Vinny, Ngu, Natalie L.Y., Kua, Hock W., Mishra, Gauri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115544/
https://www.ncbi.nlm.nih.gov/pubmed/37091207
http://dx.doi.org/10.14309/crj.0000000000001007
_version_ 1785028232791195648
author Ea, Vinny
Ngu, Natalie L.Y.
Kua, Hock W.
Mishra, Gauri
author_facet Ea, Vinny
Ngu, Natalie L.Y.
Kua, Hock W.
Mishra, Gauri
author_sort Ea, Vinny
collection PubMed
description Immune checkpoint inhibitors, such as pembrolizumab, are effective in the management of metastatic malignancies, such as melanoma, and are associated with a spectrum of immune-related organ toxicities, including immune-related hepatitis (ir-hepatitis). The clinical presentation of ir-hepatitis varies in onset and severity, and management involves immunosuppression with corticosteroids and mycophenolate mofetil as first and second-line agents. Several agents have been proposed as third-line options for treatment-refractory disease. We report the successful use of tacrolimus for delayed onset and treatment-refractory ir-hepatitis secondary to pembrolizumab.
format Online
Article
Text
id pubmed-10115544
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer
record_format MEDLINE/PubMed
spelling pubmed-101155442023-04-20 Tacrolimus for the Management of Delayed Onset and Treatment-Refractory Immune-Related Hepatitis Ea, Vinny Ngu, Natalie L.Y. Kua, Hock W. Mishra, Gauri ACG Case Rep J Case Report Immune checkpoint inhibitors, such as pembrolizumab, are effective in the management of metastatic malignancies, such as melanoma, and are associated with a spectrum of immune-related organ toxicities, including immune-related hepatitis (ir-hepatitis). The clinical presentation of ir-hepatitis varies in onset and severity, and management involves immunosuppression with corticosteroids and mycophenolate mofetil as first and second-line agents. Several agents have been proposed as third-line options for treatment-refractory disease. We report the successful use of tacrolimus for delayed onset and treatment-refractory ir-hepatitis secondary to pembrolizumab. Wolters Kluwer 2023-04-19 /pmc/articles/PMC10115544/ /pubmed/37091207 http://dx.doi.org/10.14309/crj.0000000000001007 Text en © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Case Report
Ea, Vinny
Ngu, Natalie L.Y.
Kua, Hock W.
Mishra, Gauri
Tacrolimus for the Management of Delayed Onset and Treatment-Refractory Immune-Related Hepatitis
title Tacrolimus for the Management of Delayed Onset and Treatment-Refractory Immune-Related Hepatitis
title_full Tacrolimus for the Management of Delayed Onset and Treatment-Refractory Immune-Related Hepatitis
title_fullStr Tacrolimus for the Management of Delayed Onset and Treatment-Refractory Immune-Related Hepatitis
title_full_unstemmed Tacrolimus for the Management of Delayed Onset and Treatment-Refractory Immune-Related Hepatitis
title_short Tacrolimus for the Management of Delayed Onset and Treatment-Refractory Immune-Related Hepatitis
title_sort tacrolimus for the management of delayed onset and treatment-refractory immune-related hepatitis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115544/
https://www.ncbi.nlm.nih.gov/pubmed/37091207
http://dx.doi.org/10.14309/crj.0000000000001007
work_keys_str_mv AT eavinny tacrolimusforthemanagementofdelayedonsetandtreatmentrefractoryimmunerelatedhepatitis
AT ngunataliely tacrolimusforthemanagementofdelayedonsetandtreatmentrefractoryimmunerelatedhepatitis
AT kuahockw tacrolimusforthemanagementofdelayedonsetandtreatmentrefractoryimmunerelatedhepatitis
AT mishragauri tacrolimusforthemanagementofdelayedonsetandtreatmentrefractoryimmunerelatedhepatitis

Ejemplares similares